Wee1 competitors including Zentalis might look with trepidation on Astra and Roche’s recent moves into ATR inhibition.
A look for winners and losers finds a sector laid low by poor sentiment and Covid fatigue, with Lantheus, Vertex and Jazz providing a few bright spots.
Already boasting the marketed Nubeqa, Orion licenses its next-biggest prostate cancer hope to Merck & Co.
Key upcoming clinical results approach in the third quarter for lecanemab, high-dose Eylea and Zimura.
Few sizeable transactions have emerged so far this year, with small licensing deals looking like the norm.
On the eve of Asco two deals show that the current biotech market malaise might be focusing some chief executives’ minds.